Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

239.29 +0.17 (+0.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
34 35 Next >
Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization
Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What... 
Via Benzinga
Exposures COVID-19
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease. 
Via The Motley Fool
Is There Any Hope Left for This Alzheimer's Drug Developer?
Biogen is reeling from charges that its drug doesn't work. 
Via The Motley Fool
Analyst Ratings for Biogen
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the... 
Via Benzinga
Expert Ratings For Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observe... 
Via Benzinga
How Much Should An Alzheimer's Drug Cost?
The answer is more complicated than you think. 
Via The Motley Fool
Cassava Sciences vs. Biogen
Who will emerge victorious in the race to help Alzheimer's patients? 
Via The Motley Fool
Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs
The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC:... 
Via Benzinga
What to Do After Cassava Sciences Dropped Off a Cliff
Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop. 
Via InvestorPlace
Why I Sold My Biogen Stock
It has everything to do with Aduhelm. 
Via The Motley Fool
Will Biogen Be Able to Move Past the Drama Surrounding Its Alzheimer's Disease Drug?
Probably. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Is Now a Good Time to Buy Biogen Stock?
It's a definite maybe. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Why Biogen's Stock Has Likely Peaked
The stock has a tough road back to $400, assuming it can get back there at all. 
Via The Motley Fool
Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation
Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases... 
Via Benzinga
Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday. 
Via Investor's Business Daily
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease. 
Via The Motley Fool
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
FDA approval of roxadustat seems unlikely. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis Product Safety
After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline data from a Phase 1b study of BIIB080/IONIS-MAPTRx in mild... 
Via Benzinga
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) ... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs, And More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefited from the optimism that was set in motion by the solid start to the pharma reporting... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Could These 3 Potential Blockbusters Transform Biogen?
The company is moving into three billion-dollar areas. 
Via The Motley Fool
Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell. 
Via Investor's Business Daily
Stock Market Rally Rebounds To Highs; Snap, Crocs, Chipotle, Netflix Are Key Earnings
The market rally rebounded from Monday, with the S&P 500 hitting a record high. Snap, Crocs, Chipotle were earnings winners 
Via Investor's Business Daily
Topics Earnings Stocks
Exposures Financial Fossil Fuels US Equities
Investors Too Gloomy Over Biogen Alzheimer’s Drug
There are good reasons to be skeptical that Biogen’s Aduhelm, the first new treatment for Alzheimer’s disease in nearly two decades, will change patients’ lives for the better. 
Via Talk Markets
Biogen inc (BIIB) Q2 2021 Earnings Call Transcript
BIIB earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis
On Thursday, Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance level at $117.54, made 21 years ago between its initial public offering date of June 14,... 
Via Benzinga
IGC Stock: The Huge Cannabis Patent News That Has IGC Flying High
IGC stock is moving up in a huge way today. The company is finally earning its patent for the treatment of Alzheimer's disease with cannabis. 
Via InvestorPlace
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property Product Safety
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.